U.S. Irradiation Apparatus Market Size, Share & Trends Analysis Report By Type (Gamma Rays, X-rays, Electrons, High-speed Neutrons, Alpha-beta Particles), By Application (Diagnostic, Therapeutic, Dental), End-use (Hospitals, Laboratories), And Segment Forecasts, 2025 - 2030

U.S. Irradiation Apparatus Market Size & Trends

The U.S. irradiation apparatus market size was estimated at USD 2.88 billion in 2024 and is expected to grow at a CAGR of 6.0% from 2025 to 2030. The increasing demand for non-invasive medical procedures is a significant driving factor in the growth of the irradiation apparatus market. As patients and healthcare providers seek alternatives to traditional invasive methods, non-invasive procedures, which often require precise sterilization and equipment, are gaining popularity. Furthermore, the increased usage of irradiation devices in nuclear medicine for diagnostic and therapeutic applications further propels market growth.

The increasing incidence of chronic diseases such as cancer, cardiovascular diseases, musculoskeletal disorders, prostate cancer, and breast cancer is a significant driver for the adoption of non-invasive diagnostic solutions. These conditions necessitate sophisticated imaging techniques, where X-ray and other irradiation apparatus are widely used. Such devices enable early and accurate diagnosis, allowing timely intervention and treatment that does not require invasive procedures. Furthermore, the number of cancer cases in the U.S. reached 1.9 million in 2022. According to the American Cancer Society, lung cancer is one of the most diagnosed cancers, with over 234,580 new cases expected in the U.S. in 2024 alone. Furthermore, the incidence and rate of prostate cancer in 2022 in the U.S. were 230,125. This trend enhances patient outcomes and reflects a broader shift within the healthcare sector toward non-invasive approaches that prioritize patient safety and efficacy.

The expanding scope of nuclear medicine has driven the demand for irradiation equipment that ensures high precision in medical imaging and treatment delivery. This trend underscores the critical role of irradiation apparatus in enhancing the capabilities of healthcare services in the U.S. The usage of hypo-fractionated radiotherapy contributes to notable growth in the U.S. market for irradiation apparatus. This treatment method, which delivers higher doses of radiation over fewer sessions, improves patient adherence and treatment outcomes while reducing overall healthcare costs. This approach optimizes the use of current equipment, making existing radiotherapy systems more efficient. Furthermore, it fuels demand for advanced technologies such as Image-Guided Radiation Therapy (IGRT) and Intensity-Modulated Radiation Therapy (IMRT), essential for delivering precise and effective treatment. Consequently, these advancements and treatment innovations drive market growth for irradiation apparatus in the U.S.

Furthermore, technological innovations in radiation therapies, such as intensity-modulated radiation therapy, image-guided radiation therapy, and stereotactic body radiotherapy, have enhanced cancer treatments. The trend helps to increase the radiation dose to affected tumors and, simultaneously, reduce the effects on the healthy tissues. For instance, In June 2024, Thermo Fisher Scientific launched the NetDose PRO radiation dosimeter, designed to enhance safety and accuracy in measuring radiation exposure. This device is accredited by the National Voluntary Laboratory Accreditation Program (NVLAP), ensuring it meets high safety standards. The NetDose PRO aims to improve radiation monitoring in various settings, including healthcare and research environments. The launch of Thermo Fisher Scientific's NetDose PRO radiation dosimeter highlights advancements in radiation safety technology, which is crucial for environments utilizing irradiation devices.

Market Concentration & Characteristics

The irradiation apparatus industry in the U.S. is undergoing significant growth, driven by technological advancements coupled with heightened healthcare demands and changing patient expectations. Innovations in imaging modalities, intensity-modulated radiation therapy, and advancements in e-beam technology have also focused on precision. The ability to control the radiation dose precisely minimizes exposure to surrounding materials, thereby preserving the integrity of sensitive medical devices.

Prominent service providers in the irradiation apparatus industry are actively pursuing a range of strategic initiatives, such as product approval, upgrades, collaborations, and acquisitions, to sustain their competitive advantage and address the evolving demands of the market. For instance, in February 2024, Siemens Healthineers AG received U.S. FDA 510(k) clearance to TrueBeam and Edge radiotherapy systems advanced with HyperSight imaging solution. These devices help physicians plan and offer accurate treatment to patients for their cancer treatment.

The U.S. irradiation apparatus industry is witnessing continuous advancements in imaging and cancer treatment, further driven by increasing R&D investment and a focus on precision and safety. For instance, In March 2024, researchers at Fermilab developed an electron beam accelerator to sterilize medical equipment, providing a faster, chemical-free alternative to traditional sterilization methods. This innovation uses electron beams to effectively eliminate harmful pathogens, offering a more efficient solution for the medical industry.

The U.S. irradiation apparatus industry is witnessing a notable increase in partnerships and collaborations as companies strive to expand their service offerings and engage a broader customer base. These collaborations often involve sharing advanced technologies and expertise, significantly enhancing participating organizations' service capabilities. For instance, in October 2024, IBA (Ion Beam Applications S.A.) and Jubilant Radiopharma announced a significant partnership aimed at enhancing the production of positron emission tomography (PET) radiopharmaceuticals in the U.S. This collaboration involves the installation of five Cyclone KIUBE 180 cyclotrons at various Jubilant facilities, as part of a broader USD 50 million expansion plan for their PET manufacturing network.

The U.S. irradiation apparatus market operates under stringent regulations to ensure safety, quality, and compliance, with oversight from agencies like the FDA. These regulations shape product development and market entry, reinforcing public health standards. For instance, in March 2022, the FDA granted 510(K) clearances to Radiation Medical Ltd. for its Shield System, designed to enhance radiation protection in interventional cardiology and electrophysiology procedures.

The U.S. irradiation apparatus industry faces moderate competition from alternative imaging and diagnostic methods, such as ultrasound and MRI, but irradiation remains essential for applications requiring deep tissue penetration and precise treatment.

The U.S. irradiation apparatus market is expanding regionally, with increased investment in key healthcare hubs. This growth is driven by technological demand and healthcare providers’ needs, particularly in cancer therapy and diagnostics. In September 2024, BGS Beta-Gamma-Service, a German sterilization company, is expanding its operations into the U.S. with a new facility in Pittsburgh, Pennsylvania, which is likely to focus on electron beam (e-beam) sterilization. This facility marks BGS's first location outside of Germany, where it currently operates three sterilization sites. The Pittsburgh facility is projected to become operational by mid-2025.

Type Insights

X-Rays segment held the largest market share of about 32.64% in 2024. The segment growth is driven by increasing healthcare demands, particularly for diagnostic imaging services, due to the rising prevalence of chronic diseases such as cancer and cardiovascular conditions. The transition from traditional film-based X-rays to digital systems has significantly improved image quality, processing speed, and workflow efficiency, further contributing to market expansion. Beyond diagnostics, X-ray apparatus also plays a role in radiation therapy, particularly for superficial tumors. Increasing adoption in both hospital and outpatient settings reflects its fundamental role in healthcare and the rising prevalence of chronic diseases in the U.S. that necessitate regular monitoring.

Gamma rays is expected to grow at the fastest rate of 7.1% CAGR over the forecast period, owing to factors such that gamma irradiation is cost-effective, safe, and widely used in oncology for radiotherapy and sterilizing medical devices. Increasing demand for minimally invasive cancer treatments and enhanced patient safety has fueled the adoption of gamma-ray-based equipment. It doesn't require heat, steam, strict humidity, temperature, or pressure controls. The process also doesn't significantly increase the temperature of the products, making it ideal for heat-sensitive devices. Advances in gamma ray technology, such as intensity-modulated radiation therapy (IMRT), have further optimized treatment effectiveness, particularly for complex cases. The adoption of such apparatus is supported by an increasing number of cancer patients and the need for accurate imaging solutions.

Application Insights

Diagnostics held the largest market share of about 39.91% in 2024. The demand for non-invasive diagnostics drives innovation in this segment, with developments focusing on faster imaging times and advanced features, such as 3D imaging and dose reduction technologies, for more precise diagnostics. As digital imaging technology advances, diagnostic irradiation apparatuses are increasingly capable of providing detailed images with lower radiation exposure. This enhances patient safety while supporting early disease detection, which aligns with the U.S. healthcare focus on preventive care.

The therapeutic segment is expected to grow at the fastest rate of 6.6% CAGR over the forecast period. It is vital in treating various cancers and other serious conditions, leveraging radiation's ability to target and destroy abnormal cells. Technologies such as linear accelerators, gamma knives, and proton therapy systems are central to radiotherapy. Furthermore, a few more recent developments include particle beam therapy (PBT), an advanced form of radiation therapy that precisely targets tumors while minimizing damage to surrounding healthy tissues. Several new proton therapy centers have been established across the U.S., driven by increasing investment and the potential for reduced side effects in cancer patients.

End-use Insights

Hospitals held the largest market share of about 43.7% in 2024, as hospitals are investing heavily in upgrading their medical imaging capabilities to enhance patient outcomes and operational efficiency, thereby driving growth in this segment. In addition to diagnostic equipment, therapeutic applications such as radiotherapy are critical components of hospital operations. Integrating advanced irradiation technologies, including proton beam therapy and digital imaging systems, reshapes treatment protocols and improves patient care standards. Hospitals are increasingly adopting these technologies for their effectiveness and ability to minimize radiation exposure while maximizing therapeutic benefits.

The laboratories segment is anticipated to experience the fastest growth over the forecast period. Laboratories are pivotal in advancing nuclear medicine applications, where irradiation devices are employed for diagnostic imaging and therapeutic interventions. Integrating these technologies into laboratory practices improves diagnostic accuracy and supports innovative treatment methodologies for diseases such as cancer. As laboratories continue to adopt cutting-edge irradiation technologies, they contribute significantly to the market's overall growth.

Key U.S. Irradiation Apparatus Company Insights

Major U.S. irradiation apparatus industry players are actively enhancing their product offerings to capture a larger market share and expand their customer base. These companies are investing in the latest technological upgrades to improve the quality and efficiency of their irradiation apparatus. Moreover, they are pursuing strategic acquisitions to broaden their service portfolios and enter new geographic regions, strengthening their market position. In addition, partnerships with other healthcare providers and technology firms are being formed to leverage complementary strengths and integrate innovative solutions. Securing government clearances and regulatory approvals also remains critical for these organizations.

Recent Developments

• In October 2024, Precision X-Ray partnered with Gilardoni SpA to distribute the RADGIL2 X-ray blood irradiator in the U.S. This device provides a safe and efficient method for blood irradiation, crucial in preventing transfusion-related diseases like Transfusion-associated Graft versus Host Disease (TA-GvHD).

• In August 2024, Sterigenics International, a global leader in contract sterilization and laboratory services, acquired Nordion. This strategic acquisition aims to strengthen Nordion’s position in the sterilization industry, particularly in gamma irradiation.

• In April 2024, GE Healthcare partnered with Elekta and MIM Software to enhance radiation therapy solutions. In collaboration with Elekta, GE aims to improve cancer care by integrating imaging and radiation therapy technology, streamlining workflows, and enhancing treatment precision for oncology professionals.

• In February 2024, the U.S. FDA granted 510(k) clearance to Siemens Healthineers AG’s TrueBeam and Edge radiotherapy systems advanced with HyperSight imaging solution. These devices help physicians plan and offer accurate treatment to patients for their cancer treatment.

• In February 2023, The U.S. FDA granted 510(k) clearance, and CE Market approval to Halcyon and Ethos radiotherapy systems advanced with HyperSight imaging solution developed by Varian Medical Systems, Inc. These devices help physicians plan and offer accurate cancer treatments to patients.

U.S. Irradiation Apparatus Market Report Scope

U.S. Irradiation Apparatus Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. irradiation apparatus market report based on type, application, and end-use:

• Type Outlook (Revenue, USD Billion, 2018 - 2030)

  • Gamma Rays

  • X-rays

  • High-speed Neutrons

  • Electrons

  • Alpha-beta Particles

  • Others

• Type Outlook (Revenue, USD Billion, 2018 - 2030)

  • Diagnostic

  • Therapeutic

  • Dental

  • Others

• End-use Outlook (Revenue, USD Billion, 2018 - 2030)

  • Hospitals

  • Laboratories

  • Other End Users